ArticleMolecular oncology2021
Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage.
Article in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes.JHEP reports : innovation in hepatology · 2026Article
- Gut Escherichia coli promotes lung cancer by increasing circulating STAMBP production.Discover oncology · 2025Article
- Minimally invasive biopsy-based diagnostics in support of precision cancer medicine.Molecular oncology · 2024Review
- Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma.Molecular oncology · 2023Article
- Quantitative Proteomics Indicate Radical Removal of Non-Small Cell Lung Cancer and Predict Outcome.Biomedicines · 2022Article
- Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.Molecular oncology · 2022Article
- Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer.Scientific reports · 2022Article
- Towards Building a Quantitative Proteomics Toolbox in Precision Medicine: A Mini-Review.Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarker signatures identified through minimally invasive procedures already at diagnosis of non-small-cell lung cancer (NSCLC) could help to guide treatment with immune checkpoint inhibitors (ICI). Here, we performed multiplex profiling of immune-related proteins in fine-needle aspirate (FNA) samples of thoracic lesions from patients with NSCLC to assess PD-L1 expression and identify related protein signatures. Transthoracic FNA samples from 14 patients were subjected to multiplex antibody-based profiling by proximity extension assay (PEA). PEA profiling employed protein panels relevant to immune and tumor signaling and was followed by Qlucore
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.